Concord Drugs Ltd - 538965 - Unaudited Financial Results For The Quarter Ended 31.12.2021
unaudited financial results for the quarter ended 31.12.202114-02-2022
14-02-2022
Concord Drugs Ltd - 538965 - Board Meeting Intimation for Unaudited Financial Results For The Quarter Ended 31.12.2021.
Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2022 ,inter alia, to consider and approve Unaudited financial results for the quarter ended 31.12.2021.28-01-2022
Concord Drugs Ltd - 538965 - Shareholding for the Period Ended December 31, 2021
Concord Drugs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click here19-01-2022
Concord Drugs Ltd - 538965 - Statement Of Investor Complaints For The Quarter Ended December 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Jyoti GoyalDesignation :- Company Secretary and Compliance Officer13-01-2022
Concord Drugs Ltd - 538965 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of SEBI (Depositories & Participants) Regulations, 201813-01-2022
Concord Drugs Ltd - 538965 - Disclosures under Reg. 10(7) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(7) in respect of acquisition under Regulation 10(1)(a)(i)of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for S Nagi Reddy17-11-2021
Concord Drugs Ltd - 538965 - Disclosure Of Related Party Transactions Under Regulation 23(9) Of LODR, 2015 As On 30.09.2021
Disclosure of Related Party Transactions under Regulation 23(9) of LODR, 2015 as on 30.09.202116-11-2021
Concord Drugs Ltd - 538965 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for S Nagi Reddy16-11-2021
Concord Drugs Ltd - 538965 - Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for S Nagi Reddy15-11-2021